Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Severe Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic, and Thoracic Surgery

    Summary
    EudraCT number
    2008-004835-39
    Trial protocol
    GB   DE  
    Global end of trial date
    06 Apr 2011

    Results information
    Results version number
    v1(current)
    This version publication date
    05 Aug 2016
    First version publication date
    05 Aug 2016
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    400-08-002
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00977925
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Ethicon Inc., a Johnson & Johnson Co.
    Sponsor organisation address
    Route 22 West , Somerville, United States,
    Public contact
    Jonathan Batiller, Ethicon Inc., a Johnson & Johnson Co., 001 9082182492, JBatill2@its.jnj.com
    Scientific contact
    Jonathan Batiller, Ethicon Inc., a Johnson & Johnson Co., 001 9082182492, JBatill2@its.jnj.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    06 Apr 2011
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    03 Mar 2011
    Global end of trial reached?
    Yes
    Global end of trial date
    06 Apr 2011
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the safety and haemostatic effectiveness of the Fibrin Pad (FP) versus standard of care treatment (SoC) in controlling severe soft tissue bleeding during abdominal, pelvic, retroperitoneal, and (non-cardiac) thoracic surgery.
    Protection of trial subjects
    The protocol and consent form were provided to the appropriate Ethics Committee for approval.
    Background therapy
    -
    Evidence for comparator
    The control group was treated with the surgeon's Standard of Care methods. Soc is composite of techniques/methods typically used by the surgeon to control severe bleeding after conventional methods (e.g. suture, ligature , cautery) are ineffective or impractical. For this study, SoC was to be initiated with continuous manual compression with or without gauze or sponge and with or without a topical absorbable hemostat(TAH).
    Actual start date of recruitment
    31 Aug 2009
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 21
    Country: Number of subjects enrolled
    Germany: 20
    Country: Number of subjects enrolled
    New Zealand: 29
    Country: Number of subjects enrolled
    Australia: 21
    Worldwide total number of subjects
    91
    EEA total number of subjects
    41
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    44
    From 65 to 84 years
    47
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The first subject was recruited on the 31 August 2009 and the last subject was 3 March 2011

    Pre-assignment
    Screening details
    Prospective subjects were screened within 21 days prior to surgery. Prior to any study related procedures, subjects were fully informed of all aspects of the study and asked to sign a consent form.

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded
    Blinding implementation details
    N/A

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    FIBRIN PAD
    Arm description
    FP is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components. The matrix consists of polyglactin 910 (PG910) filaments needle punched into a backing fabric of Oxidized Regenerated Cellulose (ORC). The biological components are Human Thrombin and Human Fibrinogen.
    Arm type
    Experimental

    Investigational medicinal product name
    Fibrin Pad
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Sealant matrix
    Routes of administration
    Topical use
    Dosage and administration details
    FP is intended for topical use. After placement of the treatment article, manual compression was to be applied continuously and was maintained until 4 minutes post randomization. The surgeon may have used a surgical sponge (laparotomy pad or surgical gauze) to assist in providing adequate pressure to stem all bleeding over the entire treated surface area at the TBS. A maximum of 4 units (each unit is 4 x 4 inches) of FP may have been applied (left in place at the bleeding site) per subject assigned to be treated with FP.

    Arm title
    Standard of care
    Arm description
    Standard of care
    Arm type
    Standard of care

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 1
    FIBRIN PAD Standard of care
    Started
    59
    32
    Completed
    53
    23
    Not completed
    6
    9
         Adverse event, serious fatal
    3
    2
         Consent withdrawn by subject
    2
    4
         Lost to follow-up
    1
    3

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    FIBRIN PAD
    Reporting group description
    FP is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components. The matrix consists of polyglactin 910 (PG910) filaments needle punched into a backing fabric of Oxidized Regenerated Cellulose (ORC). The biological components are Human Thrombin and Human Fibrinogen.

    Reporting group title
    Standard of care
    Reporting group description
    Standard of care

    Reporting group values
    FIBRIN PAD Standard of care Total
    Number of subjects
    59 32 91
    Age categorical
    Units: Subjects
        18 - <50 Years
    9 4 13
        50 - <65 Years
    20 11 31
        65 - <75 Years
    19 9 28
        >=75 Years
    11 8 19
    Gender categorical
    Units: Subjects
        Female
    19 15 34
        Male
    40 17 57

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    FIBRIN PAD
    Reporting group description
    FP is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components. The matrix consists of polyglactin 910 (PG910) filaments needle punched into a backing fabric of Oxidized Regenerated Cellulose (ORC). The biological components are Human Thrombin and Human Fibrinogen.

    Reporting group title
    Standard of care
    Reporting group description
    Standard of care

    Primary: Proportion of subjects achieving hemostatic success at the TBS at 4 minutes after randomization with no rebleeding requiring treatment at the TBS at any time prior to wound closure

    Close Top of page
    End point title
    Proportion of subjects achieving hemostatic success at the TBS at 4 minutes after randomization with no rebleeding requiring treatment at the TBS at any time prior to wound closure
    End point description
    End point type
    Primary
    End point timeframe
    4 minutes after randomization
    End point values
    FIBRIN PAD Standard of care
    Number of subjects analysed
    59
    32
    Units: Achievement of hemostasis
    50
    10
    Statistical analysis title
    Primary efficacy endpoint
    Comparison groups
    FIBRIN PAD v Standard of care
    Number of subjects included in analysis
    91
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.0001
    Method
    Chi-squared
    Confidence interval

    Secondary: Proportion of subjects achieving hemostatic success at 10 minutes following randomization

    Close Top of page
    End point title
    Proportion of subjects achieving hemostatic success at 10 minutes following randomization
    End point description
    End point type
    Secondary
    End point timeframe
    10 minutes after randomization
    End point values
    FIBRIN PAD Standard of care
    Number of subjects analysed
    59
    32
    Units: Hemostatic success
    58
    22
    Statistical analysis title
    Secondary endpoint analysis
    Comparison groups
    FIBRIN PAD v Standard of care
    Number of subjects included in analysis
    91
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0001
    Method
    Logistics model
    Parameter type
    Log odds ratio
    Point estimate
    2.384
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.949
         upper limit
    3.819

    Secondary: Absolute time to hemostasis

    Close Top of page
    End point title
    Absolute time to hemostasis
    End point description
    Absolute time to hemostasis is defined as the absolute time to achieve hemostasis at or after 4 minutes from randomization.
    End point type
    Secondary
    End point timeframe
    Absolute time to hemostasis
    End point values
    FIBRIN PAD Standard of care
    Number of subjects analysed
    59
    32
    Units: Minutes
        arithmetic mean (confidence interval 95%)
    6.1 (2.5 to 9.6)
    17.8 (6.1 to 29.6)
    No statistical analyses for this end point

    Secondary: Proportion of subjects requiring retreatment at the TBS prior to wound closure

    Close Top of page
    End point title
    Proportion of subjects requiring retreatment at the TBS prior to wound closure
    End point description
    End point type
    Secondary
    End point timeframe
    Between 4 minutes and wound closure
    End point values
    FIBRIN PAD Standard of care
    Number of subjects analysed
    59
    32
    Units: Number requiring retreatment
    3
    17
    Statistical analysis title
    Secondary endpoint analysis
    Comparison groups
    FIBRIN PAD v Standard of care
    Number of subjects included in analysis
    91
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.0001
    Method
    Logistic model
    Parameter type
    Log odds ratio
    Point estimate
    -2.462
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.661
         upper limit
    -1.262

    Secondary: Incidence of treatment failure

    Close Top of page
    End point title
    Incidence of treatment failure
    End point description
    Treatment failure is defined as hemostasis was not achieved within 4 minutes or if bleeding requiring retreatment prior to wound closure.
    End point type
    Secondary
    End point timeframe
    Prior to wound closure
    End point values
    FIBRIN PAD Standard of care
    Number of subjects analysed
    59
    32
    Units: Number of treatment failures
    9
    22
    Statistical analysis title
    Secondary endpoint analysis
    Comparison groups
    FIBRIN PAD v Standard of care
    Number of subjects included in analysis
    91
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.0001
    Method
    Logistic model
    Parameter type
    Log odds ratio
    Point estimate
    -2.354
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.503
         upper limit
    -1.205

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    AE's were collected from the start of randomization, during the procedure, throughout hospital admission and until completion of the 60 day follow up visit.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    10.1
    Reporting groups
    Reporting group title
    FIBRIN PAD
    Reporting group description
    FP is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components. The matrix consists of polyglactin 910 (PG910) filaments needle punched into a backing fabric of Oxidized Regenerated Cellulose (ORC). The biological components are Human Thrombin and Human Fibrinogen.

    Reporting group title
    Standard of care
    Reporting group description
    Standard of care

    Serious adverse events
    FIBRIN PAD Standard of care
    Total subjects affected by serious adverse events
         subjects affected / exposed
    15 / 59 (25.42%)
    10 / 32 (31.25%)
         number of deaths (all causes)
    4
    3
         number of deaths resulting from adverse events
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Bladder cancer
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Injury, poisoning and procedural complications
    Anastomotic leak
         subjects affected / exposed
    0 / 59 (0.00%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pancreatic leak
    Additional description: 1
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Post procedural bile leak
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary anastomotic leak
         subjects affected / exposed
    0 / 59 (0.00%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vascular disorders
    Haemorrhage
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Subclavian vein thrombosis
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vena cava thrombosis
         subjects affected / exposed
    0 / 59 (0.00%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Cardiac disorder
         subjects affected / exposed
    0 / 59 (0.00%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 59 (0.00%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Disease progression
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Gastrointestinal disorders
    Ascites
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Faecaloma
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Impaired gastric emptying
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Localised intraabdominal fluid collection
         subjects affected / exposed
    0 / 59 (0.00%)
    2 / 32 (6.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hepatorenal syndrome
         subjects affected / exposed
    0 / 59 (0.00%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Respiratory, thoracic and mediastinal disorders
    Aspiration
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    Atelectasis
         subjects affected / exposed
    0 / 59 (0.00%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    2 / 59 (3.39%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumothorax
         subjects affected / exposed
    1 / 59 (1.69%)
    2 / 32 (6.25%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary oedema
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory distress
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    0 / 59 (0.00%)
    3 / 32 (9.38%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Musculoskeletal and connective tissue disorders
    Musculoskeletal pain
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Bacterial sepsis
         subjects affected / exposed
    0 / 59 (0.00%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Empyema
         subjects affected / exposed
    1 / 59 (1.69%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Lower respiratory tract infection
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    1 / 59 (1.69%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 59 (0.00%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Subdiaphragmatic abscess
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    1 / 59 (1.69%)
    1 / 32 (3.13%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Wound infection
         subjects affected / exposed
    2 / 59 (3.39%)
    2 / 32 (6.25%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hyperglycaemia
         subjects affected / exposed
    1 / 59 (1.69%)
    0 / 32 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    FIBRIN PAD Standard of care
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    58 / 59 (98.31%)
    32 / 32 (100.00%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    4 / 59 (6.78%)
    1 / 32 (3.13%)
         occurrences all number
    6
    2
    Hypotension
         subjects affected / exposed
    23 / 59 (38.98%)
    16 / 32 (50.00%)
         occurrences all number
    26
    19
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    4 / 59 (6.78%)
    0 / 32 (0.00%)
         occurrences all number
    4
    0
    Hypothermia
         subjects affected / exposed
    5 / 59 (8.47%)
    2 / 32 (6.25%)
         occurrences all number
    5
    2
    Oedema peripheral
         subjects affected / exposed
    3 / 59 (5.08%)
    5 / 32 (15.63%)
         occurrences all number
    3
    6
    Pain
         subjects affected / exposed
    18 / 59 (30.51%)
    14 / 32 (43.75%)
         occurrences all number
    20
    15
    Pyrexia
         subjects affected / exposed
    11 / 59 (18.64%)
    13 / 32 (40.63%)
         occurrences all number
    16
    15
    Respiratory, thoracic and mediastinal disorders
    Atelectasis
         subjects affected / exposed
    7 / 59 (11.86%)
    2 / 32 (6.25%)
         occurrences all number
    7
    2
    Cough
         subjects affected / exposed
    5 / 59 (8.47%)
    3 / 32 (9.38%)
         occurrences all number
    5
    3
    Dyspnoea
         subjects affected / exposed
    3 / 59 (5.08%)
    1 / 32 (3.13%)
         occurrences all number
    3
    1
    Hiccups
         subjects affected / exposed
    2 / 59 (3.39%)
    3 / 32 (9.38%)
         occurrences all number
    2
    3
    Hypoxia
         subjects affected / exposed
    3 / 59 (5.08%)
    1 / 32 (3.13%)
         occurrences all number
    3
    1
    Pleural effusion
         subjects affected / exposed
    9 / 59 (15.25%)
    7 / 32 (21.88%)
         occurrences all number
    10
    10
    Pneumothorax
         subjects affected / exposed
    4 / 59 (6.78%)
    2 / 32 (6.25%)
         occurrences all number
    4
    2
    Respiratory failure
         subjects affected / exposed
    1 / 59 (1.69%)
    3 / 32 (9.38%)
         occurrences all number
    1
    3
    Tachypnoea
         subjects affected / exposed
    1 / 59 (1.69%)
    3 / 32 (9.38%)
         occurrences all number
    1
    4
    Psychiatric disorders
    Agitation
         subjects affected / exposed
    3 / 59 (5.08%)
    2 / 32 (6.25%)
         occurrences all number
    3
    2
    Insomnia
         subjects affected / exposed
    5 / 59 (8.47%)
    4 / 32 (12.50%)
         occurrences all number
    5
    4
    Investigations
    Blood fibrinogen increased
         subjects affected / exposed
    2 / 59 (3.39%)
    2 / 32 (6.25%)
         occurrences all number
    3
    3
    Blood magnesium decreased
         subjects affected / exposed
    5 / 59 (8.47%)
    1 / 32 (3.13%)
         occurrences all number
    5
    1
    Blood phosphorus decreased
         subjects affected / exposed
    0 / 59 (0.00%)
    2 / 32 (6.25%)
         occurrences all number
    0
    2
    Haemoglobin decreased
         subjects affected / exposed
    5 / 59 (8.47%)
    0 / 32 (0.00%)
         occurrences all number
    5
    0
    Lymphocyte count decreased
         subjects affected / exposed
    3 / 59 (5.08%)
    2 / 32 (6.25%)
         occurrences all number
    4
    2
    Platelet count increased
         subjects affected / exposed
    2 / 59 (3.39%)
    2 / 32 (6.25%)
         occurrences all number
    2
    2
    Renal function test
         subjects affected / exposed
    0 / 59 (0.00%)
    2 / 32 (6.25%)
         occurrences all number
    0
    2
    Injury, poisoning and procedural complications
    Anaesthetic complication
         subjects affected / exposed
    0 / 59 (0.00%)
    2 / 32 (6.25%)
         occurrences all number
    0
    2
    Procedural hypotension
         subjects affected / exposed
    1 / 59 (1.69%)
    2 / 32 (6.25%)
         occurrences all number
    1
    2
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    5 / 59 (8.47%)
    3 / 32 (9.38%)
         occurrences all number
    5
    3
    Bradycardia
         subjects affected / exposed
    7 / 59 (11.86%)
    5 / 32 (15.63%)
         occurrences all number
    7
    6
    Cardiac disorder
         subjects affected / exposed
    2 / 59 (3.39%)
    2 / 32 (6.25%)
         occurrences all number
    2
    2
    Tachycardia
         subjects affected / exposed
    5 / 59 (8.47%)
    3 / 32 (9.38%)
         occurrences all number
    8
    5
    Nervous system disorders
    Lethargy
         subjects affected / exposed
    1 / 59 (1.69%)
    2 / 32 (6.25%)
         occurrences all number
    1
    2
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    11 / 59 (18.64%)
    7 / 32 (21.88%)
         occurrences all number
    12
    12
    Coagulopathy
         subjects affected / exposed
    0 / 59 (0.00%)
    2 / 32 (6.25%)
         occurrences all number
    0
    4
    Leukocytosis
         subjects affected / exposed
    1 / 59 (1.69%)
    2 / 32 (6.25%)
         occurrences all number
    1
    2
    Gastrointestinal disorders
    Abdominal distension
         subjects affected / exposed
    4 / 59 (6.78%)
    1 / 32 (3.13%)
         occurrences all number
    4
    1
    Abdominal pain
         subjects affected / exposed
    6 / 59 (10.17%)
    3 / 32 (9.38%)
         occurrences all number
    8
    3
    Constipation
         subjects affected / exposed
    26 / 59 (44.07%)
    11 / 32 (34.38%)
         occurrences all number
    26
    12
    Diarrhoea
         subjects affected / exposed
    9 / 59 (15.25%)
    6 / 32 (18.75%)
         occurrences all number
    11
    7
    Localised intraabdominal fluid collection
         subjects affected / exposed
    1 / 59 (1.69%)
    2 / 32 (6.25%)
         occurrences all number
    1
    2
    Nausea
         subjects affected / exposed
    35 / 59 (59.32%)
    14 / 32 (43.75%)
         occurrences all number
    39
    16
    Vomiting
         subjects affected / exposed
    16 / 59 (27.12%)
    9 / 32 (28.13%)
         occurrences all number
    17
    12
    Skin and subcutaneous tissue disorders
    Decubitus ulcer
         subjects affected / exposed
    3 / 59 (5.08%)
    1 / 32 (3.13%)
         occurrences all number
    3
    1
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    3 / 59 (5.08%)
    0 / 32 (0.00%)
         occurrences all number
    3
    0
    Oliguria
         subjects affected / exposed
    7 / 59 (11.86%)
    5 / 32 (15.63%)
         occurrences all number
    7
    7
    Musculoskeletal and connective tissue disorders
    Musculoskeletal pain
         subjects affected / exposed
    4 / 59 (6.78%)
    0 / 32 (0.00%)
         occurrences all number
    5
    0
    Infections and infestations
    Lower respiratory tract infection
         subjects affected / exposed
    4 / 59 (6.78%)
    5 / 32 (15.63%)
         occurrences all number
    5
    5
    Oral candidiasis
         subjects affected / exposed
    4 / 59 (6.78%)
    2 / 32 (6.25%)
         occurrences all number
    4
    2
    Pneumonia
         subjects affected / exposed
    1 / 59 (1.69%)
    4 / 32 (12.50%)
         occurrences all number
    2
    5
    Sepsis
         subjects affected / exposed
    3 / 59 (5.08%)
    4 / 32 (12.50%)
         occurrences all number
    3
    4
    Urinary tract infection
         subjects affected / exposed
    5 / 59 (8.47%)
    2 / 32 (6.25%)
         occurrences all number
    5
    2
    Wound infection
         subjects affected / exposed
    4 / 59 (6.78%)
    2 / 32 (6.25%)
         occurrences all number
    5
    2
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    4 / 59 (6.78%)
    0 / 32 (0.00%)
         occurrences all number
    4
    0
    Dehydration
         subjects affected / exposed
    3 / 59 (5.08%)
    2 / 32 (6.25%)
         occurrences all number
    3
    2
    Hypoalbuminaemia
         subjects affected / exposed
    1 / 59 (1.69%)
    2 / 32 (6.25%)
         occurrences all number
    1
    2
    Hypokalaemia
         subjects affected / exposed
    10 / 59 (16.95%)
    6 / 32 (18.75%)
         occurrences all number
    11
    6
    Hyponatraemia
         subjects affected / exposed
    4 / 59 (6.78%)
    1 / 32 (3.13%)
         occurrences all number
    4
    1
    Hypophosphataemia
         subjects affected / exposed
    1 / 59 (1.69%)
    2 / 32 (6.25%)
         occurrences all number
    1
    2

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    22 Feb 2010
    Amendment 2 - Clarification around: Interim analysis TBS definition exclusion of sealants for SoC subjects. venue of study centers SAE definition In addition there was an increase in number of sites and an addition of a 60-day follow up visit

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Please note that there are 2 subjects (Pt 15019 and 20007) who died after completion of their participation in the study. These deaths are included in the adverse events provided.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 16:18:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA